(Q43048511)

12 November 2017

title

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations (English)

1 reference

cost-effectiveness analysis

12 November 2017

main subject

1 reference

Jackson BR

1

1 reference

12 November 2017

Busch MP

series ordinal

2

1 reference

12 November 2017

Stramer SL

series ordinal

3

1 reference

12 November 2017

AuBuchon JP

series ordinal

4

1 reference

12 November 2017

publication date

1 June 2003

1 reference

12 November 2017

1 reference

12 November 2017

volume

43

1 reference

12 November 2017

issue

6

1 reference

12 November 2017

page(s)

721-729

1 reference

Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00392.X

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00392.X

The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00392.X

Long-term survival in transfusion recipients in Sweden, 1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00392.X

A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00392.X

NAT of the United States and Canadian blood supply

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00392.X

The cost effectiveness of combination antiretroviral therapy for HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00392.X

Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00392.X

Safety of the blood supply in the United States: opportunities and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00392.X

A cost-effectiveness analysis of the use of a mechanical barrier system to reduce the risk of mistransfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1537-2995.2003.00392.X

10.1046/J.1537-2995.2003.00392.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference